

25 March 2009
BioPharmica (ASX: BPH) ASX Announcement

Molecular Discovery Systems High Content Screening Service 'Characterisation of Protein Expression'

Professor Kanti Bhoola of the Centre for Asthma, Allergy and Respiratory Research, The Lung Institute of Western Australia (LIWA) contracted Molecular Discovery Systems (MDSYSTEMS) a wholly owned subsidiary of BioPharmica Limited in December 2008 to assist in the characterisation of protein expression in human lung and mesothelioma cancer cells. The expression of 5 proteins within these cells, as well as their response to treatment was required to support previous findings within Professor Bhoola's research program.

Image capture and analysis of the prepared plates was conducted at the MDSYSTEMS laboratory by trained personnel to provide the result of analysis documents detailing protein location and abundance. With the first phase of the project nearing completion with highly satisfactory results, preparation for the next phase of the project 'The effect of Bradykinin on mitogenesis,' has begun. As a result of this work, interest has been generated as to other potential applications of the InCell Analyser 1000 for research purposes. MDSYSTEMS and LIWA are currently negotiating the incorporation of MDSYSTEMS' analysis technology into other research programs.

The MDSYSTEMS owned InCell Analyser 1000 combines high resolution imaging and high-content analysis to provide a technology that rapidly detects and quantifies components of the cell much faster than conventional methods. Molecular Discovery Systems is available for contract work for more details go to: <http://biopharmica.com.au/portfolio/mds/index.html>



Molecular Discovery Systems

Molecular Discovery Systems (MDSYSTEMS) is a wholly owned subsidiary of BioPharmica Limited [ASX: BPH] which was established in 2006. MDSYSTEMS has expertise in verification and validation of both assays and analysis. The main business of the company is drug discovery with the validation of Biomarkers for disease, therapy and diagnostics.



Lung Institute of Western Australia

The Lung Institute of Western Australia Incorporated (LIWA) is a charitable organisation and is one of only two research institutes in Australia dedicated specifically to investigating lung disease. Historically the Institute has had a strong interest in allergic airway disease but has now broadened this to encompass all lung diseases. The institute carefully integrates basic scientific and clinical research to help better understand lung disorders and to improve their treatment. In its day to day activities LIWA is making a vital contribution to the quality of life of many Australians and to people worldwide.

Yours sincerely,

David Breeze
Chairman

For further information please contact:

Mr David Breeze
Chairman
BioPharmica Limited
Tel : +61 9 9328 8366

Ms Rachel Ramsdale
Research Scientist
Molecular Discovery Systems
Tel: +61 8 9 346 7404